Corticosteroids in the initial treatment of Kawasaki disease: Report of a randomized trial

Journal of Pediatrics

Volumn 142, Issue 6, 2003, Pages 611-616

  Sundel, Robert P ^a   Baker, Annette L ^a   Fulton, David R ^a   Newburger, Jane W ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DOSE CALCULATION; DRUG TOLERANCE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; HYPERTENSION; INFANT; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TIME;

EID: 0038133014     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2003.191     Document Type: Article

References (28)

1. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1954;2:1055-8.
2. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy E, et al. The treatment of Kawasaki syndrome with intravenous gamma gobulin. N Engl J Med 1986;315:341-7.
3. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-61.
4. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent ofsalicylate dose. J Pediatr 1997;131:888-93.
5. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80.
6. Lentsch AB, Ward PA. Regulation of inflammatory vascular damage. J Pathol 2000;190:343-8.
7. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
8. Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999;135:465-9.
9. Dale RC, Saleem MA, Daw S, Dillon MJ. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr 2000;137:723-6.
10. Nonaka Z, Maekawa K, Okabe T, Eto Y, Kubo M. Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. In: Kato H, editor. Kawasaki disease. Amsterdam (The Netherlands): Elsevier Science; 1994.
11. Kijima Y, Kamiya T, Suzuki A, Hirose O, Manabe H. A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jpn Circ J 1982;46:1239-42.
12. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1998;128:146-9.
13. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-7.
14. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatr 2000;105:E78.
15. Dahlem PG, von Rosenstiel IA, Lain J, Kuijpers TW. Pulse methylprednisolone therapy for impending cardiac tamponade in immunoglobulin-resistant Kawasaki disease. Intensive Care Med 1999;25:1137-9.
16. Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamatlon of the fingers and toes in children]. Arerugi 1967;16:178-222.
17. de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 2000;133:254-8.
18. Barron KS, Shulman ST, Rowley A, Taubert K, Myones BL, Meissner HC, et al. Report of the National Institutes of Health Workshop on Kawasaki disease. J Rheumatol 1999;26:170-90.
19. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-7.
20. Baylis EM, Williams IA, English J, Marks V, Chakraborty J. High-dose intravenous methylprednisolone "pulse" therapy in patients with rheumatoid disease. Plasma methylprednisolone levels and adrenal function. Eur J Clin Pharmacol 1982;21:385-8.
21. Youssef PP, Triantafillou S, Parker A, Coleman M, Roberts-Thomson PJ, Ahem MJ, et al. Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression. Arthritis Rheum 1996;39:1970-9.
22. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinfiammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1992;89:9991-5.
23. Youssef PP, Haynes DR, Triantafillou S, Parker A, Gamble JR, Roberts-Thomson PJ, et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum 1997;40:1400-8.
24. Watanabe S, Nishiyama M, Shimizu J. Re-evaluation study in Kawasaki disease patients without coronary arterial lesions. In: Kato H, editor. Kawasaki disease. Amsterdam (The Netherlands): Elsevier; 1995. p. 619-23.
25. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
26. Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986;108:388-92.
27. Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr 1994;124:721-5.
28. Morikawa Y, Ohashi Y, Harada K, Asai T, Okawa S, Nagashima M, et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatr Int 2000;42:464-9.